AI Article Synopsis
- * A reported case involved an APL patient who had both the JAK2 V617F mutation and the t(15;17) translocation, leading to transformation into a myeloproliferative neoplasm (PV/ET) after treatment.
- * After successful initial treatment that achieved complete remission, the patient experienced a relapse where the JAK2 V617F mutation persisted, eventually leading to a condition that responded well to interferon therapy.
Article Abstract
Background: The V617F mutation of Janus-associated kinase 2 (JAK2) is common in myeloproliferative neoplasms (MPN). JAK2 V617F mutation can be detected in patients with acute myeloid leukemia (AML), but acute promyelocytic leukemia (APL) with JAK2 V617F mutation is rare.
Case Presentation: We report a case of APL with both the t(15;17) translocation as well as the JAK2 V617F mutation that transformed into MPN (PV/ET).
Conclusions: A APL patient presented initially with JAK2 V617F. After ATRA and ATO dual induction and chemotherapy consolidation, the patient achieved complete remission (CR) with undetectable PML/RAR. However, the JAK2 V617F remained positive, and the patient developed MPN (PV/ET) 22 months later, which responded well to interferon therapy.AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; ATO, arsenic trioxide; BM, bone marrow; CR, complete remission; ET, essential thrombocythemia; Hb, hemoglobin; JAK2, Janus-associated kinase 2; MPN, myeloproliferative neoplasms; PLT, platelets; PMF, primary myelofibrosis; PML/RAR; PV, polycythemia vera; WBC, white blood cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/16078454.2022.2153200 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!